A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma U.S., Inc. in Cambridge, MA is seeking a Director, Applied AI/ML and Statistics to lead machine learning and statistical methods across biological, chemical and imaging data.
You will decide models, adapt them to data, and build reusable translational data science programs within Research. You will collaborate with Translational Medicine, Modeling & Simulation and Biometrics to connect multi-modal patient data with research questions and to identify biomarkers, shaping drug
As Director, Applied AI/ML and Statistics, Research, you will be Zealand Pharma’s expert in applying machine learning and statistical methods across biological, chemical and imaging data. You will decide which models and statistical methods are fit for which questions, adapt them to our data, and make them reliable and reusable across Research. You will lead translational data science projects that connect patient-derived multi-modal data with research and translational questions. You will also contribute to scientific and technology projects across our obesity and metabolic health pipeline.
You are a hands-on machine learning scientist with breadth across data types and the judgment to know when a model is good enough for a decision. You move easily between a benchmark, a biology question and an engineering conversation. You explain complex results simply to scientists and senior leaders, and you push back when the evidence does not support the claim. You thrive in a growing team where you can shape how models are chosen, shared and used across Research.
Research AI and Computational Sciences is part of Discovery Research. The team brings data science, AI and computational methods into Zealand Pharma’s research, from target discovery to candidate nomination.
It works across our research sites in Copenhagen, Denmark and Cambridge, Massachusetts. It collaborates closely with chemistry, biology, modelling and simulation, clinical development, and Digital, Data & Technology. The position reports to the VP, Head of Research AI and Computational Sciences.
We have a unique culture, characterised by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development.
The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialisation. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.
Learn more at www.zealandpharma.com
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialisation partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.